AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.01016-06v1
51/1/386    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Obert, C. A.
Right arrow Articles by Tuomanen, E. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Obert, C. A.
Right arrow Articles by Tuomanen, E. I.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2007, p. 386-389, Vol. 51, No. 1
0066-4804/07/$08.00+0     doi:10.1128/AAC.01016-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Quinupristin-Dalfopristin Nonsusceptibility in Pneumococci from Sickle Cell Disease Patients{triangledown}

Caroline A. Obert,1,{dagger} Martha L. Miller,1,{dagger},{ddagger} Jeremy Montgomery,1,§ Thomas Adamkiewicz,2 and Elaine I. Tuomanen1*

Department of Infectious Diseases, St. Jude Children's Research Hospital, 332 North Lauderdale, Memphis, Tennessee 38105,1 Department of Family Medicine, Morehouse School of Medicine, 1513 E. Cleveland, No. 100, East Point, Georgia 303442

Received 14 August 2006/ Returned for modification 11 September 2006/ Accepted 16 October 2006

Sickle cell disease (SCD) is a risk factor for fatal pneumococcal infection. Nonsusceptibilty to quinupristin-dalfopristin (Q-D) was absent from 105 non-SCD-associated pneumococcal isolates but was present in 33/148 (22%) SCD-associated isolates. One-third of the isolates harbored a known resistance mechanism. Q-D is not optimal for use for the treatment of pneumococcal infection in SCD patients.

* Corresponding author. Mailing address: Department of Infectious Diseases, St. Jude Children's Research Hospital, 332 North Lauderdale St., Memphis, TN 38105-2794. Phone: (901) 495-3486. Fax: (901) 495-3099. E-mail: elaine.tuomanen{at}stjude.org.

{triangledown} Published ahead of print on 23 October 2006.

{dagger} These two authors contributed equally to this project.

{ddagger} Present address: Department of Pediatrics, Division of Infectious Diseases, The University of New Mexico, 1 University of New Mexico, Albuquerque, NM 87131.

§ Present address: Middle Tennessee State University, 1301 East Main Street, Murfreesboro, TN 37132.

Antimicrobial Agents and Chemotherapy, January 2007, p. 386-389, Vol. 51, No. 1
0066-4804/07/$08.00+0     doi:10.1128/AAC.01016-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.